Stockscreener 앱 받기
4.77
1.45%
-0.07
전일 마감가:
$4.84
열려 있는:
$4.87
하루 거래량:
182.62K
Relative Volume:
0.92
시가총액:
$216.06M
수익:
$84.82M
순이익/손실:
$-21.43M
주가수익비율:
-9.7347
EPS:
-0.49
순현금흐름:
$-27.23M
1주 성능:
+10.67%
1개월 성능:
-2.85%
6개월 성능:
-23.68%
1년 성능:
-61.31%
1일 변동 폭
$4.68
$4.90
1주일 범위
$4.29
$5.005
52주 변동 폭
$3.55
$16.11
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
명칭
Y Mabs Therapeutics Inc
전화
646-885-8505
주소
202 CARNEGIE CENTER, PRINCETON, NY
YMAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
4.77 | 219.23M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-22 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-11-18 | 개시 | Oppenheimer | Outperform |
| 2024-08-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-06-28 | 개시 | Truist | Buy |
| 2023-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-04-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-01-27 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-01-05 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-12-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-10-31 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-10-31 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재개 | Guggenheim | Buy |
| 2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-11-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-04-23 | 재개 | Cowen | Outperform |
| 2021-03-22 | 재개 | JP Morgan | Overweight |
| 2021-01-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2020-05-01 | 개시 | Janney | Buy |
| 2020-04-29 | 개시 | Morgan Stanley | Equal-Weight |
| 2019-12-24 | 개시 | JP Morgan | Overweight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-09-04 | 개시 | Wedbush | Outperform |
| 2019-04-01 | 개시 | H.C. Wainwright | Buy |
| 2018-10-16 | 개시 | BTIG Research | Buy |
| 2018-10-16 | 개시 | BofA/Merrill | Buy |
모두보기
Y Mabs Therapeutics Inc 주식(YMAB)의 최신 뉴스
What drives Y mAbs Therapeutics Inc. stock priceFree Stock Market Beginners Guide - PrintWeekIndia
YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know - MSN
What analysts say about Y mAbs Therapeutics Inc. stockFree Predictions - PrintWeekIndia
Will Y mAbs Therapeutics Inc. stock benefit from AI tech trendsHigh-profit capital plays - jammulinksnews.com
Should I buy Y mAbs Therapeutics Inc. stock before earningsFree Predictions - jammulinksnews.com
Will Y mAbs Therapeutics Inc. stock split in the near futureUnprecedented profit potential - jammulinksnews.com
Following a 61% decline over last year, recent gains may please Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) institutional owners - simplywall.st
How the (YMAB) price action is used to our Advantage - news.stocktradersdaily.com
Is Y mAbs Therapeutics Inc. a good long term investmentMarket-beating performance - jammulinksnews.com
Y mAbs Therapeutics Inc. Stock Analysis and ForecastUnrivaled growth potential - Autocar Professional
Y-Mabs Therapeutics Elects New Director at Annual Meeting - TipRanks
Y-mAbs Therapeutics announces results of annual shareholder meeting votes - Investing.com
What makes Y mAbs Therapeutics Inc. stock price move sharplySafe and Smart Investment Picks - Newser
Why Y mAbs Therapeutics Inc. stock attracts strong analyst attentionFree Risk Assessment Services - Newser
2nd Circ. Affirms Biotech Founder's Win In Trading Suit - Law360
Transcript : Y-mAbs Therapeutics, Inc.Shareholder/Analyst Call - MarketScreener
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
YMAB SEC FilingsY-Mabs Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Is Y-mAbs Therapeutics, Inc. overvalued or undervalued? - MarketsMojo
Cantor Fitzgerald Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Overweight Recommendation - MSN
Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles - Investing.com India
Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles By Investing.com - Investing.com South Africa
Y Mabs Therapeutics Inc (YMAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
0.22%
자본화:
|
볼륨(24시간):